BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol 2016;64:301-7. [PMID: 26476290 DOI: 10.1016/j.jhep.2015.10.005] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association 2020;119:1019-40. [DOI: 10.1016/j.jfma.2020.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
2 Schneider MD, Sarrazin C. Management of HCV-Associated Liver Cirrhosis. Visc Med 2016;32:96-104. [PMID: 27413726 DOI: 10.1159/000445330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Chan HL, Tsang OT, Hui YT, Fung J, Lui GC, Lai CL, Wong GL, Chan KH, But DY, Lai MS, Lao WC, Chan CK, Lam YS, Seto WK, Li C, Yuen MF, Wong VW. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. J Gastroenterol Hepatol 2017;32:1230-3. [PMID: 27869328 DOI: 10.1111/jgh.13663] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
4 Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, Carnicer F, Rincón D, Salmerón J, Mateos-Muñoz B, Jou A, Polo-Lorduy B, Rubín Á, Escarda A, Aguilar P, Aldámiz-Echevarría T, García-Buey L, Carrión JA, Hernández-Guerra M, Chimeno-Hernández S, Espinosa N, Morillas RM, Andrade RJ, Delgado M, Gallego A, Magaz M, Moreno-Planas JM, Estébanez Á, Rico M, Menéndez F, Sampedro B, Morano L, Izquierdo S, Zozaya JM, Rodríguez M, Morán-Sánchez S, Lorente S, Martín-Granizo I, Von-Wichmann MÁ, Delgado M, Manzanares A. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS One 2019;14:e0225061. [PMID: 31714950 DOI: 10.1371/journal.pone.0225061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chamorro-de-vega E, Gimenez-manzorro A, Rodriguez-gonzalez CG, Escudero-vilaplana V, Collado Borrell R, Ibañez-garcia S, Lallana Sainz E, Lobato Matilla E, Lorenzo-pinto A, Manrique-rodriguez S, Fernandez-llamazares CM, Marzal-alfaro M, Ribed A, Romero Jimenez RM, Sarobe Gonzalez C, Herranz A, Sanjurjo M. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice. Ann Pharmacother 2016;50:901-8. [DOI: 10.1177/1060028016659306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
6 Daloul R, Pesavento T, Goldberg DS, Reese PP. A review of kidney transplantation from HCV-viremic donors into HCV-negative recipients. Kidney Int 2021:S0085-2538(21)00669-4. [PMID: 34237327 DOI: 10.1016/j.kint.2021.06.034] [Reference Citation Analysis]
7 Chan J, Chung RT. Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions. Clinical Pharmacology in Drug Development 2017;6:147-63. [DOI: 10.1002/cpdd.338] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
8 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
9 Zampino R, Vitrone M, Parrella A, Ragone E, Durante-Mangoni E. Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases. J Chemother 2018;30:129-30. [PMID: 28925824 DOI: 10.1080/1120009X.2017.1376782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Preda CM, Popescu CP, Baicus C, Voiosu TA, Manuc M, Pop CS, Gheorghe L, Sporea I, Trifan A, Tantau M, Tantau A, Ceausu E, Proca D, Constantinescu I, Ruta SM, Diculescu MM, Oproiu A. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver Int 2018;38:602-10. [PMID: 28816020 DOI: 10.1111/liv.13550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
11 Zarębska-Michaluk D. Viral hepatitis C treatment shortening - what is the limit? Clin Exp Hepatol 2019;5:265-70. [PMID: 31893236 DOI: 10.5114/ceh.2019.88085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Juanbeltz R, Goñi Esarte S, Úriz-Otano JI, Martínez Echeverría A, Elizalde I, Zozaya JM, Castilla J, San Miguel R. Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgrad Med 2017;129:476-83. [PMID: 28343408 DOI: 10.1080/00325481.2017.1311197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
13 Ilyas SZ, Tabassum R, Hamed H, Rehman SU, Qadri I. Hepatitis C Virus-Associated Extrahepatic Manifestations in Lung and Heart and Antiviral Therapy-Related Cardiopulmonary Toxicity. Viral Immunol 2017;30:633-41. [PMID: 28953449 DOI: 10.1089/vim.2017.0009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
14 Zarębska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M. Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther 2020;18:1033-44. [PMID: 32579414 DOI: 10.1080/14787210.2020.1776112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
16 Mohazzab-torabi S, Dolatimehr F, Sharafi H, Safi-abadi M, Rezaee-zavareh MS, Bayatpour E, Karimi-sari H, Alavian SM. Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.82971] [Reference Citation Analysis]
17 Akaberi D, Bergfors A, Kjellin M, Kameli N, Lidemalm L, Kolli B, Shafer RW, Palanisamy N, Lennerstrand J. Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach. Infect Ecol Epidemiol 2018;8:1528117. [PMID: 30319736 DOI: 10.1080/20008686.2018.1528117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A. Current and future challenges in HCV: insights from an Italian experts panel. Infection 2018;46:147-63. [PMID: 29098647 DOI: 10.1007/s15010-017-1093-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Mendizabal M, Haddad L, Gallardo PE, Ferrada A, Soza AA, Adrover R, Aravena E, Roblero JP, Prieto J, Vujacich C, Romero G, Muñoz A, Anders M, Hernández N, Coccozella D, Gruz F, Reggiardo MV, Ruf AE, Varón A, Cartier M, Pérez Ravier R, Ridruejo E, Peralta M, Poncino D, Vorobioff J, Aballay Soteras G, Silva MO. Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America. J Med Virol 2017;89:1590-6. [DOI: 10.1002/jmv.24816] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
20 Fofiu C, Boeriu A, Coman F, Fofiu A, Panic N, Bulajic M, Dobru D. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Ann Hepatol 2019;18:137-43. [PMID: 31113582 DOI: 10.5604/01.3001.0012.7905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A, Tabone M, Andreoni M, Teti E, Angelico M, Persico M, Masarone M, Chiodera A, Solinas A, delle Monache M, Cecere R, Maria Schimizzi A, Piovesan S, Campagnolo D, Chiara Piras M, Zolfino T, Paolo Russo F, Morelli O, Sangiovanni V, Onofrio M, Iodice V, Izzi A, Pirisi M, Danieli E, Vinci M, Rizzardini G, Fagiuoli S, Pasulo L, D'arminio Monforte A, Zuin M, Giorgini A, Simeone F, Piali G, Lo Guercio C, Federico A, Brancaccio G, Marrone A, Abbati G, Boarini C, Borghi V, Bernabucci V, Corti G, Monti M, Rizzetto M, Martini S, Andreone P, Gianstefani A, Lenzi M, Verucchi G, Toniutto P, Borgia G, Caporaso N, Morisco F, Nardone G, Angrisani D, Giacometti A, Benedetti A, Tarantino G, Marsetti F, Tavio M, Novara S, Antonia Santantonio T, Serviddio G, Brunetto M, Coco B, Angarano G, Milella M, Barone M, Di Leo A, Ettore Sansonno D, Cacciola I, Boffa N, Saracco G, Di Biagio A, Picciotto A, de Luca A, Calvaruso V, Corradori S, Ferrari C, Orlandini A, Maida I, Torti C, Chessa L, Felder M, Vespasiani Gentilucci U, Angeli P, Romano A, Ludovico Rapaccini G, Miele L, Cima S, Luisa Russo M, Cozzolongo R, Onnelli G, D'offizi G, Lionetti R, Montalbano M, Guerra M, Di Perri G, Boglione L, Capra F, Carolo G, Ieluzzi D, Antonini C, Termite A, Madonia S, Tarquini P, Parruti G, Vecchiet G, Falasca K, Menzaghi B, Quirino T, Dentone C, Maria Piscaglia A, Rossi C, Giordani M, Fontanella L, Cassola G, Russello M, Cristaudo A, Giacomet V, Colombo M, Donato F, Durante E, Cosco L, Marignani M, Quartini M, Memoli M, Ganga R, Ponti L, Soria A, Grazia Rumi M, Gulminetti R, Maserati R, Mondelli M, Lazzarin A, Rita Parisi M, Canovari B, Avancini I, Pravadelli C, Blanc P, Pasquazzi C, Maria Mastroianni C, Lichtner M, Distefano M, Magnani S, Paganin S, Erne E, Gatti P, Tundi P, Calabrese P, Gasbarrini A, Grieco A, Coppola N, Del Poggio P, Levrero M, Talliani G, Vullo V, Cauda R, La Monica S, Potenza D, Rizzo S, Castelli F, Marie Pigozzi G, Ciancio A, Romagnoli D, Barchetti F, Ivanovic J, Longo O, Petraglia S, Paola Trotta M. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology & Hepatology 2017;2:427-34. [DOI: 10.1016/s2468-1253(17)30048-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
22 Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH. Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. J Formos Med Assoc 2019;118:1014-23. [PMID: 30448077 DOI: 10.1016/j.jfma.2018.10.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. J Gastroenterol Hepatol 2019;34:364-9. [PMID: 30144366 DOI: 10.1111/jgh.14447] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
24 Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, Vassiliadis T, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, Dalekos GN, Akriviadis E, Papatheodoridis GV. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease. Br J Haematol 2017;178:130-6. [PMID: 28439915 DOI: 10.1111/bjh.14640] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
25 Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:25-35. [PMID: 28404108 DOI: 10.1016/S2468-1253(16)30001-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
26 Zha J, Ding B, Wang H, Zhao W, Yu C, Alves K, Mobashery N, Luo Y, Menon RM. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. Eur J Drug Metab Pharmacokinet 2019;44:43-52. [PMID: 29909549 DOI: 10.1007/s13318-018-0492-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C, Stefanescu G, Girleanu I, Chiriac S, Mihai C, Brisc C, Goldis A, Sporea I, Miftode E, Bataga S, Rogoveanu I, Preda C, Caruntu FA, Singeap AM. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine (Baltimore) 2017;96:e9271. [PMID: 29390377 DOI: 10.1097/MD.0000000000009271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
28 Wang YK, Lee WP, Wang YW, Huang YH, Hou MC, Chang YL, Lan KH. Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir. J Chin Med Assoc 2020;83:1071-8. [PMID: 33273269 DOI: 10.1097/JCMA.0000000000000429] [Reference Citation Analysis]
29 Weiler N, Zeuzem S, Welker MW. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol 2016; 22(41): 9044-9056 [PMID: 27895394 DOI: 10.3748/wjg.v22.i41.9044] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
30 Ferenci P. New anti-HCV drug combinations: who will benefit? Lancet Infect Dis 2017;17:1008-9. [PMID: 28818545 DOI: 10.1016/S1473-3099(17)30486-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
31 Cabalak M, Bal T, Onlen Y, Demir M. Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection. Trop Doct 2020;50:141-6. [PMID: 31810415 DOI: 10.1177/0049475519892082] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Danilau D, Malich N, Litvinchuk D, Karpov I. Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus. Clin Exp Hepatol 2017;3:164-8. [PMID: 29062907 DOI: 10.5114/ceh.2017.70281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
33 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194. [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001] [Cited by in Crossref: 712] [Cited by in F6Publishing: 649] [Article Influence: 118.7] [Reference Citation Analysis]
34 Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Wyles DL, Schnell G, Alami NN, Zhang Z, Dumas E, Dore GJ. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infect Dis 2018;5:ofy248. [PMID: 30430131 DOI: 10.1093/ofid/ofy248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Forde KA, Bhattacharya D. Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. Curr Treat Options Infect Dis 2017;9:262-76. [PMID: 29805320 DOI: 10.1007/s40506-017-0124-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
36 Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, De Lorenzo-Pinto A, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo Saez M; GRUviC Study Group. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study. Expert Opin Drug Saf 2018;17:235-41. [PMID: 29325476 DOI: 10.1080/14740338.2018.1424829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
37 Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E, Mobashery N, Tatsch F, Foster GR. Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. J Hepatol. 2017;67:700-707. [PMID: 28645740 DOI: 10.1016/j.jhep.2017.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
38 Li X, Chan NS, Tam AW, Hung IFN, Chan EW. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. Eur J Clin Microbiol Infect Dis. 2017;36:1801-1809. [PMID: 28516201 DOI: 10.1007/s10096-017-2995-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
39 Sarıgul F, Sayan M, User U, Oztoprak N. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.62390] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Hull MW, Yoshida EM, Montaner JS. Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Curr Infect Dis Rep 2016;18:22. [PMID: 27357277 DOI: 10.1007/s11908-016-0527-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
41 Zachoval R, Jung MC. [Chronic Hepatitis C - Therapeutic Options in 2016]. MMW Fortschr Med 2016;158 Suppl 1:54-7. [PMID: 27259905 DOI: 10.1007/s15006-016-8329-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Talal AH, Dumas EO, Bauer B, Rejman RM, Ocque A, Morse GD, Lucic D, Cloherty GA, King J, Zha J, Zhang H, Cohen DE, Shulman N, Pawlotsky JM, Hézode C. Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage. J Infect Dis 2018;217:474-82. [PMID: 29228392 DOI: 10.1093/infdis/jix495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
43 Isakov V, Paduta D, Viani RM, Enejosa JV, Pasechnikov V, Znoyko O, Ogurtsov P, Bogomolov PO, Maevskaya MV, Chen X, Shulman NS. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV). Eur J Gastroenterol Hepatol 2018;30:1073-6. [PMID: 29762255 DOI: 10.1097/MEG.0000000000001166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Galati G, Rampa L, Vespasiani-Gentilucci U, Marino M, Pisani F, Cota C, Guidi A, Picardi A. Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy. World J Hepatol 2016; 8(29): 1244-1250 [PMID: 27803769 DOI: 10.4254/wjh.v8.i29.1244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
45 Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, Renjifo B, Wang D, Shuster DL, Cohen DE, Jacobson IM. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Kidney Int Rep 2019;4:245-56. [PMID: 30775621 DOI: 10.1016/j.ekir.2018.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Chen CH, Chen CH, Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, Lu SN, Chien RN, Hung CH, Sheen IS. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Sci Rep 2019;9:7086. [PMID: 31068655 DOI: 10.1038/s41598-019-43554-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
47 Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. J Gastroenterol Hepatol 2018;33:710-7. [PMID: 28762541 DOI: 10.1111/jgh.13912] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
48 Perelló C, Carrión JA, Ruiz-antorán B, Crespo J, Turnes J, Llaneras J, Lens S, Delgado M, García-samaniego J, García-paredes F, Fernández I, Morillas RM, Rincón D, Porres JC, Prieto M, Lázaro Ríos M, Fernández-rodríguez C, Hermo JA, Rodríguez M, Herrero JI, Ruiz P, Fernández JR, Macías M, Pascasio JM, Moreno JM, Serra MÁ, Arenas J, Real Y, Jorquera F, Calleja JL; the Spanish Collaborative Group for the Study of the Use of Hepatitis C Direct-Acting Drugs. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. J Viral Hepat 2017;24:226-37. [DOI: 10.1111/jvh.12637] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
49 Wu SH, Chu CJ, Lin CC, Su CW, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. J Chin Med Assoc 2019;82:186-90. [PMID: 30908411 DOI: 10.1097/JCMA.0000000000000069] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy 2018;62:94-103. [DOI: 10.1016/j.drugpo.2018.10.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
51 San SN, Matsumoto J, Saito Y, Koike M, Sakaue H, Kato Y, Fujiyoshi M, Ariyoshi N, Yamada H. Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. Xenobiotica 2019;49:935-44. [PMID: 30227770 DOI: 10.1080/00498254.2018.1524947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Rolt A, Talley DC, Park SB, Hu Z, Dulcey A, Ma C, Irvin P, Leek M, Wang AQ, Stachulski AV, Xu X, Southall N, Ferrer M, Liang TJ, Marugan JJ. Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly. J Med Chem 2021;64:9431-43. [PMID: 34184537 DOI: 10.1021/acs.jmedchem.1c00696] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Ferenci P. Current Treatment of Chronic Hepatitis C. Liver Pathophysiology. Elsevier; 2017. pp. 781-9. [DOI: 10.1016/b978-0-12-804274-8.00056-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
55 Neukam K, Morano-amado LE, Rivero-juárez A, Mancebo M, Granados R, Téllez F, Collado A, Ríos MJ, de los Santos-gil I, Reus-bañuls S, Vera-méndez F, Geijo-martínez P, Montero-alonso M, Suárez-santamaría M, Pineda JA. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. HIV Clinical Trials 2017;18:126-34. [DOI: 10.1080/15284336.2017.1330801] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
56 Khan RJ, Jha RK, Amera GM, Jain M, Singh E, Pathak A, Singh RP, Muthukumaran J, Singh AK. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase. J Biomol Struct Dyn 2021;39:2679-92. [PMID: 32266873 DOI: 10.1080/07391102.2020.1753577] [Cited by in Crossref: 70] [Cited by in F6Publishing: 84] [Article Influence: 35.0] [Reference Citation Analysis]
57 Gschwantler M, Bamberger T, Graziadei I, Maieron A, Katalinic N, Stauber R. Burden of disease in patients with chronic hepatitis C in the Austrian REAL study. Wien Klin Wochenschr 2019;131:8-16. [PMID: 30430232 DOI: 10.1007/s00508-018-1404-2] [Reference Citation Analysis]
58 Corman S, Elbasha EH, Michalopoulos SN, Nwankwo C. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value in Health 2017;20:1110-20. [DOI: 10.1016/j.jval.2017.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
59 de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017;5:Doc08. [PMID: 30671330 DOI: 10.3205/id000034] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
60 Wang LS, D'Souza LS, Jacobson IM. Hepatitis C-A clinical review. J Med Virol. 2016;88:1844-1855. [PMID: 27097298 DOI: 10.1002/jmv.24554] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
61 Cenderello G, Fanizza C, Marenco S, Nicolini LA, Artioli S, Baldissarro I, Dentone C, De Leo P, Di Biagio A. Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. Clinicoecon Outcomes Res 2017;9:281-93. [PMID: 28579812 DOI: 10.2147/CEOR.S129859] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
62 Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Bialkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Rostkowska K, Piekarska A, Tronina O, Madej G, Garlicki A, Lucejko M, Pisula A, Karpińska E, Kryczka W, Wiercińska-Drapało A, Mozer-Lisewska I, Jabłkowski M, Horban A, Knysz B, Tudrujek M, Halota W, Simon K. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther 2016;44:946-56. [PMID: 27611776 DOI: 10.1111/apt.13790] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
63 Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Hüppe D, Manns MP, Mauss S. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterol J 2018;6:213-24. [PMID: 29511551 DOI: 10.1177/2050640617716607] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
64 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
65 Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118-126. [PMID: 29024739 DOI: 10.1016/j.pharmthera.2017.10.009] [Cited by in Crossref: 97] [Cited by in F6Publishing: 83] [Article Influence: 19.4] [Reference Citation Analysis]
66 Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat 2017;24:840-9. [DOI: 10.1111/jvh.12708] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
67 Lu M, Wu KH, Li J, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Rupp LB, Zhang T, Trudeau S, Gordon SC. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat. 2019;26:1210-1217. [PMID: 31197910 DOI: 10.1111/jvh.13162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
68 Saab S, Mehta D, Hudgens S, Grunow N, Bao Y, Pinsky B. Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C. Liver Int 2018;38:1377-94. [PMID: 29314597 DOI: 10.1111/liv.13690] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA, Abdel-Daim MM. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. Clin Drug Investig 2017;37:1009-23. [PMID: 28871475 DOI: 10.1007/s40261-017-0565-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
70 Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, Di Marco V, Lampertico P, Brunetto MR, Zuin M, Andreone P, Villa E, Troshina G, Calvaruso V, Degasperi E, Coco B, Giorgini A, Conti F, Di Leo A, Marzi L, Boccaccio V, Bollani S, Maisonneuve P, Bruno S. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;47:1705-1712. [PMID: 29722439 DOI: 10.1111/apt.14685] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
71 Muñoz-Gómez R, Rincón D, Ahumada A, Hernández E, Devesa MJ, Izquierdo S, Ortiz M, Hernández-Albujar A, Fernández-Rodríguez C, Calvo M, González R, Lozano M, Castellano G, Fernández-Vázquez I. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. J Viral Hepat 2017;24:464-71. [PMID: 27976490 DOI: 10.1111/jvh.12664] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
72 Zarębska-michaluk D, Jaroszewicz J, Janczewska E, Berak H, Horban A, Sitko M, Garlicki A, Dobracka B, Czauż-andrzejuk A, Dybowska D, Halota W, Pawłowska M, Tudrujek-zdunek M, Tomasiewicz K, Mazur W, Deroń Z, Belica-wdowik T, Baka-ćwierz B, Buczyńska I, Simon K, Piekarska A, Białkowska-warzecha J, Lorenc B, Krygier R, Staniaszek A, Klapaczyński J, Citko J, Socha Ł, Wawrzynowicz-syczewska M, Laurans Ł, Flisiak R. Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.80761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Turnes J, Domínguez-hernández R, Casado MÁ. Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. Gastroenterología y Hepatología 2017;40:433-46. [DOI: 10.1016/j.gastrohep.2017.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
74 Dent M, Hamorsky K, Vausselin T, Dubuisson J, Miyata Y, Morikawa Y, Matoba N. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. Cell Mol Gastroenterol Hepatol 2021;11:185-98. [PMID: 32861832 DOI: 10.1016/j.jcmgh.2020.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Maan R, van der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res 2016;5:F1000 Faculty Rev-367. [PMID: 27006761 DOI: 10.12688/f1000research.7399.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
76 D'Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol. 2017;24:31-37. [PMID: 28419938 DOI: 10.1016/j.coviro.2017.03.017] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 11.8] [Reference Citation Analysis]
77 Navarro-Triviño FJ, Muñoz-Medina L, Navarro-Navarro I, Ruiz-Villaverde R. Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we presumed. Int J Dermatol 2018;57:493-4. [PMID: 29359336 DOI: 10.1111/ijd.13882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Flisiak R, Flisiak-Jackiewicz M. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2017;11:559-67. [PMID: 28317409 DOI: 10.1080/17474124.2017.1309284] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
79 Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int 2017;37:5-18. [PMID: 27473533 DOI: 10.1111/liv.13212] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 10.2] [Reference Citation Analysis]
80 Poordad F, Bennett M, Sepe TE, Cohen E, Reindollar RW, Everson G, Phillips RW, Siddique A, Sullivan JG, Pilot-Matias T, Abunimeh M, Cohen DE, Younes Z. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy. J Med Virol 2019;91:1307-12. [PMID: 30840774 DOI: 10.1002/jmv.25448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Ponziani FR, Siciliano M, Lionetti R, Pasquazzi C, Gianserra L, D'Offizi G, Gasbarrini A, Pompili M. Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. Am J Kidney Dis 2017;70:297-300. [PMID: 28258770 DOI: 10.1053/j.ajkd.2017.01.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
82 de Leuw P, Stephan C. Protease inhibitor therapy for hepatitis C virus-infection. Expert Opin Pharmacother 2018;19:577-87. [PMID: 29595065 DOI: 10.1080/14656566.2018.1454428] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
83 Pessoa MG, Ramalho-Madruga JV, Alves K, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Correa MC, Ferraz ML, Ferreira PRA, Álvares-da-Silva MR, Coelho HS, Affonso-de-Araújo ES, Furtado J, Parana R, Silva G, Lari SA, Liu L, Tripathi R, Pilot-Matias T, Cohen DE, Shulman NS, Martinelli A. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis. Ann Hepatol 2018;17:959-68. [PMID: 30600291 DOI: 10.5604/01.3001.0012.7196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Calleja JL, Crespo J, Rincón D, Ruiz-antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-samaniego J, Sacristán B, García-eliz M, Llerena S, Pascasio JM, Turnes J, Torras X, Morillas RM, Llaneras J, Serra MA, Diago M, Rodriguez CF, Ampuero J, Jorquera F, Simon MA, Arenas J, Navascues CA, Bañares R, Muñoz R, Albillos A, Mariño Z. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. Journal of Hepatology 2017;66:1138-48. [DOI: 10.1016/j.jhep.2017.01.028] [Cited by in Crossref: 113] [Cited by in F6Publishing: 104] [Article Influence: 22.6] [Reference Citation Analysis]
85 Saad MF, Alenezi S, Asker H; Kuwait Hepatology Club. Expert opinion on the management of hepatitis C infection in Kuwait. Hepat Med. 2018;10:117-132. [PMID: 30319294 DOI: 10.2147/hmer.s154842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Liver Int 2018;38:1571-5. [PMID: 29377566 DOI: 10.1111/liv.13708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
87 Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski M. Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. J Viral Hepat 2017;24:280-6. [DOI: 10.1111/jvh.12641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
88 Hussaini T. Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review. Hepat Med. 2016;8:61-68. [PMID: 27274322 DOI: 10.2147/hmer.s72429] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
89 Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Open Forum Infect Dis 2017;4:ofx154. [PMID: 28948180 DOI: 10.1093/ofid/ofx154] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
90 Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Infection 2018;46:607-15. [PMID: 29808463 DOI: 10.1007/s15010-018-1157-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
91 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
92 Castellote J, Gea F, Morano LE, Morillas RM, Pineda JA, Vergara M, Buti M. Factors influencing hepatitis C cure in the era of direct-acting antivirals. Gastroenterol Hepatol 2019;42 Suppl 1:1-7. [PMID: 32560767 DOI: 10.1016/S0210-5705(20)30181-3] [Reference Citation Analysis]
93 Deutsch L, Houri I, Ben-Ari Z, Shlomai A, Veitsman E, Cohen-Ezra O, Issachar A, Mor O, Gozlan Y, Bruck R, Menachem Y, Zelber-Sagi S, Katchman H, Shibolet O. Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial. BMC Infect Dis 2020;20:264. [PMID: 32245397 DOI: 10.1186/s12879-020-4921-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
94 Zeuzem S. Treatment Options in Hepatitis C. Dtsch Arztebl Int 2017;114:11-21. [PMID: 28143635 DOI: 10.3238/arztebl.2017.0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
95 Butt AA, Ren Y, Marks K, Shaikh OS, Sherman KE; ERCHIVES study. Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES. Aliment Pharmacol Ther 2017;45:150-9. [PMID: 27813162 DOI: 10.1111/apt.13837] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
96 Mensing S, Polepally AR, König D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. AAPS J 2016;18:270-80. [PMID: 26597291 DOI: 10.1208/s12248-015-9846-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
97 Wedemeyer H, Craxí A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, Calleja JL. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat 2017;24:936-43. [PMID: 28480525 DOI: 10.1111/jvh.12722] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
98 Torun D, Soydas B, Tekkarismaz N, Ozelsancak R, Micozkadioglu H, Haberal M. Experience with antiviral agents for treatment of hepatitis C virus infection in hemodialysis patients on the kidney wait list. Hemodial Int 2019;23:E78-82. [PMID: 30762283 DOI: 10.1111/hdi.12719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Park SH. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1]. Korean J Gastroenterol 2016;67:127-31. [PMID: 26996181 DOI: 10.4166/kjg.2016.67.3.127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
100 King JR, Zha J, Khatri A, Dutta S, Menon RM. Clinical Pharmacokinetics of Dasabuvir. Clin Pharmacokinet 2017;56:1115-24. [PMID: 28258380 DOI: 10.1007/s40262-017-0519-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
101 Arends J, Kracht P, Hoepelman A. Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clinical Microbiology and Infection 2016;22:846-52. [DOI: 10.1016/j.cmi.2016.05.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
102 Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239 [PMID: 31143073 DOI: 10.3748/wjg.v25.i18.2229] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Taramasso L, Di Biagio A, Bovis F, Nicolini LA, Antinori A, Milazzo L, Sollima S, Gubertini G, Niero F, Saracino A, Bruno R, Borghi V, Montagnani F, Cattelan A, Hasson H, Taliani G, D'Arminio Monforte A, Mastroianni C, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Cacopardo B, Giacometti A, Parruti G, Vullo V, Chirianni A, Teti E, Pasquazzi C, Segala D, Andreoni M. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One 2018;13:e0192627. [PMID: 29462201 DOI: 10.1371/journal.pone.0192627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
104 Jie Y, Lin C, Yuan J, Zhao Z, Guan Y, Zhou Y, Zhou X, Zhong B, Ye Y, Zhang L, Tao L, Li J, Zhang X, Chong Y. Real-world effectiveness and safety of OBT/PTV/r and dasabuvir for patients with chronic HCV genotype 1b infection in China: A multicenter prospective observational study. Liver Research 2020;4:153-8. [DOI: 10.1016/j.livres.2020.06.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Puigvehí M, De Cuenca B, Viu A, Diago M, Turnes J, Gea F, Pascasio JM, Lens S, Cabezas J, Badia E, Olveira A, Morillas RM, Torras X, Montoliu S, Cordero P, Castro JL, Salmerón J, Molina E, Sánchez-Ruano JJ, Moreno J, Antón MD, Moreno JM, De la Vega J, Calleja JL, Carrión JA. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort. Liver Int 2019;39:90-7. [PMID: 30160363 DOI: 10.1111/liv.13950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
106 Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, von Hahn T, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker MW, Harrer E, Scholten S, Hinterleitner C, Lauer UM, Malek NP, Berg CP. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. PLoS One 2018;13:e0197544. [PMID: 29874250 DOI: 10.1371/journal.pone.0197544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
107 Jancoriene L, Polubenko K, Kazenaite E, Buivydiene A, Jakutiene J, Tolmane I, Jeruma A, Radzisauskiene D, Mockiene E, Ambrozaitis A. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Ashraf MU, Iman K, Khalid MF, Salman HM, Shafi T, Rafi M, Javaid N, Hussain R, Ahmad F, Shahzad-Ul-Hussan S, Mirza S, Shafiq M, Afzal S, Hamera S, Anwar S, Qazi R, Idrees M, Qureshi SA, Chaudhary SU. Evolution of efficacious pangenotypic hepatitis C virus therapies. Med Res Rev 2019;39:1091-136. [PMID: 30506705 DOI: 10.1002/med.21554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
109 Gopalakrishnan S, Mensing S, Menon RM, Zha J. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies. Clin Pharmacokinet 2018;57:1407-19. [PMID: 29516428 DOI: 10.1007/s40262-018-0640-y] [Reference Citation Analysis]
110 Shuster DL, Menon RM, Ding B, Khatri A, Li H, Cohen E, Jewett M, Cohen DE, Zha J. Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials. Eur J Clin Pharmacol 2019;75:207-16. [PMID: 30291369 DOI: 10.1007/s00228-018-2566-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]